🇺🇸 AMGN — Amgen Inc.

Healthcare Compra
← Volver

Precio actual

437,23 USD

Máx. histórico

447,03

10 días

Split 2:1 del 22/11/1999

Caída desde máximo

-2,19%

Rango 52 semanas

269,77 – 447,03

Variación hoy

-1,55%

Cierre anterior

444,12

Rango de hoy

435,01 – 441,66

Volumen hoy

1.656.089

Información
Nombre completo
Amgen Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
31.500
PER
27,17 (puede no estar actualizado)
Dividend yield
2,31% (puede no estar actualizado)
Precio objetivo analistas
389,69 USD (puede no estar actualizado)
Primera cotización
17/06/1983
Precio actualizado
hace 3 días
Sobre la empresa

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Dividendos repartidos Total últimos 12 meses: 9,9400 USD · Yield: 2,27%
Fecha de pago Importe por participación
12/05/2015 0,7900 USD
10/02/2015 0,7900 USD
10/11/2014 0,6100 USD
12/08/2014 0,6100 USD
13/05/2014 0,6100 USD
11/02/2014 0,6100 USD
12/11/2013 0,4700 USD
14/08/2013 0,4700 USD
14/05/2013 0,4700 USD
11/02/2013 0,4700 USD
13/11/2012 0,3600 USD
14/08/2012 0,3600 USD
14/05/2012 0,3600 USD
13/02/2012 0,3600 USD
15/11/2011 0,2800 USD
Splits Registrados en el histórico de precios
Fecha Ratio
22/11/1999 2:1
01/03/1999 2:1
16/08/1995 2:1
11/09/1991 3:1
13/08/1990 2:1
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
19/09/2007 56,00 56,59 55,50 55,80 -0,37% 1,95% 9.915.500
18/09/2007 55,41 56,07 54,38 56,01 +0,99% 3,05% 11.513.500
17/09/2007 55,65 55,99 54,51 55,46 -1,53% 2,66% 10.125.100
14/09/2007 56,88 56,88 55,89 56,32 -1,40% 1,74% 8.891.300
13/09/2007 55,80 57,27 55,75 57,12 +2,66% 2,72% 18.552.100
12/09/2007 55,22 56,82 54,65 55,64 +3,27% 3,93% 27.971.900
11/09/2007 51,08 54,38 51,00 53,88 +5,56% 6,62% 22.311.000
10/09/2007 50,85 51,76 50,85 51,04 +0,28% 1,79% 6.786.100
07/09/2007 51,17 52,20 50,67 50,90 -2,13% 2,99% 13.801.900
06/09/2007 52,65 52,79 51,80 52,01 -0,59% 1,88% 10.949.600
05/09/2007 53,23 53,39 52,11 52,32 +1,91% 2,40% 20.417.400
04/09/2007 50,27 51,46 50,11 51,34 +2,45% 2,69% 9.014.400
31/08/2007 50,09 50,50 50,00 50,11 +0,06% 1,00% 8.929.300
30/08/2007 49,50 50,48 49,50 50,08 -0,22% 1,98% 8.693.000
29/08/2007 49,88 50,26 49,06 50,19 +2,41% 2,41% 14.028.800
28/08/2007 49,59 49,92 49,01 49,01 -1,82% 1,84% 9.514.700
27/08/2007 49,81 50,78 49,50 49,92 -0,70% 2,57% 5.361.300
24/08/2007 50,38 50,47 50,00 50,27 +0,04% 0,93% 8.330.100
23/08/2007 49,16 51,00 49,16 50,25 +1,93% 3,74% 11.249.700
22/08/2007 49,56 49,59 48,80 49,30 +0,12% 1,59% 10.811.000
21/08/2007 49,25 49,98 49,09 49,24 -1,10% 1,81% 8.204.600
20/08/2007 49,81 50,51 49,00 49,79 -0,58% 3,03% 9.450.600
17/08/2007 49,59 50,10 48,30 50,08 +1,36% 3,63% 17.597.000
16/08/2007 49,49 50,01 48,54 49,41 -2,33% 2,97% 17.405.400
15/08/2007 50,91 51,65 50,49 50,59 -1,42% 2,28% 21.209.500
14/08/2007 51,26 51,95 51,15 51,32 +0,12% 1,56% 8.339.200
13/08/2007 51,05 51,98 50,89 51,26 +2,36% 2,14% 10.331.400
10/08/2007 50,37 50,92 49,71 50,08 -1,78% 2,40% 14.413.700
09/08/2007 51,60 52,50 50,98 50,99 -1,94% 2,95% 11.271.500
08/08/2007 51,53 52,00 50,75 52,00 +1,19% 2,43% 10.734.700